Accelerate To Win: The Challenges Of Dosage Form Development

The race to bring innovative therapies into the clinic is accelerating, placing new demands on drug product development. While much attention is focused on streamlining clinical trials, the ability to efficiently develop and manufacture high-quality dosage forms remains a critical factor in keeping programs on track. Without suitable clinical supplies, even the most promising candidates cannot advance.

As development progresses, dosage form requirements evolve rapidly. Early-stage programs prioritize flexibility and speed, often relying on simple formulations that support dose-escalation studies. Later phases require scalable, robust drug products capable of supporting larger trials and eventual commercialization. Navigating this transition successfully requires careful planning across formulation development, analytical methods, excipient selection, stability testing, and manufacturing process design.

CDMOs play an increasingly important role in helping companies manage these complexities, providing specialized expertise and development capabilities that support both speed and long-term manufacturability. Explore the key considerations that help maintain development momentum while building a strong foundation for future clinical and commercial success.